The advances in immunotherapy biomarkers of small cell lung cancer

谢梦青; 储香玲; 周　娟; 苏春霞

doi:10.19401/j.cnki.1007-3639.2021.07.010

您当前的位置：

首页 >

文章列表页 >

The advances in immunotherapy biomarkers of small cell lung cancer

更新时间：2025-12-31

- The advances in immunotherapy biomarkers of small cell lung cancer
- China Oncology Vol. 31, Issue 7, Pages: 635-639(2021)
- 作者机构：
  
  同济大学附属上海市肺科医院肿瘤科,上海,200433
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2021.07.010
  CLC：
- Published Online：04 August 2021，
  
  Published：04 August 2021
- 稿件说明：
移动端阅览
谢梦青, 储香玲, 周　娟, 苏春霞. 小细胞肺癌免疫治疗相关生物标志物研究进展[J]. 中国癌症杂志, 2021, 31(7): 635-639.

谢梦青, 储香玲, 周　娟, et al. The advances in immunotherapy biomarkers of small cell lung cancer[J]. China Oncology, 2021, 31(7): 635-639.
谢梦青, 储香玲, 周　娟, 苏春霞. 小细胞肺癌免疫治疗相关生物标志物研究进展[J]. 中国癌症杂志, 2021, 31(7): 635-639. DOI： 10.19401/j.cnki.1007-3639.2021.07.010.

谢梦青, 储香玲, 周　娟, et al. The advances in immunotherapy biomarkers of small cell lung cancer[J]. China Oncology, 2021, 31(7): 635-639. DOI： 10.19401/j.cnki.1007-3639.2021.07.010.

摘要

最近30年来小细胞肺癌（small cell lung cancer，SCLC）的治疗手段无明显突破，整体预后也无显著改善。随着免疫治疗时代的开启，免疫检查点抑制剂在SCLC治疗中取得了重大进展，但整体获益仍有限。如何筛选获益人群以进一步提高免疫治疗效果是当下SCLC研究的热点问题之一。通过概述SCLC现状，聚焦SCLC免疫治疗相关生物标志物，综述近年来SCLC免疫治疗标志物研究现状与进展，以期为未来优化免疫治疗策略提供线索和思路。

Abstract

There is no obvious breakthrough in treatment for small cell lung cancer (SCLC) in more than 30 years

and the prognosis has not improved significantly. With the opening of the immune era

immune checkpoint inhibitors have made breakthroughs in SCLC treatment

but the overall benefit population is limited. How to select patients accurately and how to increase the efficacy of immunotherapy are hot topics in SCLC research. Therefore

this article summarized the current status of SCLC with focus on biomarkers related to SCLC immunotherapy

reviewed the progress in the research of immunotherapy markers in recent years

to provide clues and ideas for future immunotherapeutic strategies.

关键词

Keywords

references

Views

5174

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research status and progress of third-line treatment for metastatic colorectal cancer

Significant fundamental translational research on breast cancer in China: progress and prospects

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Related Author

Jingyu LIU

Tong YIN

Yue WU

Xiaobo PENG

Xianbao ZHAN

Yufeng LU

Han WANG

Yifan XIE

Related Institution

Department of Oncology, The First Affiliated Hospital of Naval Medical University

Department of Breast Surgery, Fudan University Shanghai Cancer Center/Fudan University Breast Cancer Institute, Department of Oncology, Shanghai Medical College, Fudan University

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

AI问答

⁰